Marvel Biosciences Corp

As of April 30, 2026, Marvel Biosciences Corp carries a market capitalization of 10.71M, placing it among publicly traded companies globally. Its enterprise value stands at 11.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Marvel Biosciences Corp has 63.03M shares outstanding.

These figures are as of April 30, 2026.

As of April 30, 2026, Marvel Biosciences Corp maintains a current ratio of 0.18, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -51.06, indicating conservative leverage, while an interest coverage ratio of -2.41 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended April 30, 2026. Return on assets (ROA) is negative at -286.21, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Marvel Biosciences Corp's stock has declined approximately 39.47% over the past 52 weeks. The 50-day moving average sits at 0.14, while the 200-day moving average is 0.15.

Over the twelve months ended April 30, 2026, Marvel Biosciences Corp generated - - in revenue and converted that into -1.39M in net income, yielding earnings per share of -0.02. EBITDA reached -759,750.00, while operating income came in at -764,036.00.

As of April 30, 2026, Marvel Biosciences Corp holds 434,800.00 in cash and equivalents against 1.40M in total debt, resulting in a net debt position of 961,200.00. Total book value stands at -2.73M, with working capital of -2.11M providing operational flexibility.

Marvel Biosciences Corp produced -778,838.00 in operating cash flow over the twelve months ended April 30, 2026.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -8.03: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -7.70, meaning Marvel Biosciences Corp raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of April 30, 2026, Marvel Biosciences Corp has an Altman Z-Score of -47.62, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.